Tianjin Development Holdings (HK:0882) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Tianjin Development Holdings has renewed its agreements with Tianjin Pharmaceutical Group for a year starting January 2025, ensuring continued connected transactions. The agreements involve the sale of chemical drugs and pharmaceutical products, with pricing aligned to market conditions and similar to third-party offerings. These transactions are subject to reporting and review requirements but are exempt from needing shareholder approval.
For further insights into HK:0882 stock, check out TipRanks’ Stock Analysis page.
